A case of marginal zone B cell lymphoma mimicking IgG4-related dacryoadenitis and sialoadenitis by unknown
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Background: IgG4-related dacryoadenitis and sialoadenitis (IgG4-DS), so-called Mikulicz’s disease, is characterized by
elevated serum IgG4 and infiltration of IgG4-positive plasma cells in glandular tissues. Recently, several studies reported
both malignant lymphoma developed on the background of IgG4-associated conditions and IgG4-producing
malignant lymphoma (non-IgG4-related disease).
Case presentation: We report on the case of a 70-year-old man who was strongly suspected IgG4-DS because of high
serum IgG4 concentration (215 mg/dl) and bilateral swelling of parotid and submandibular glands. Biopsies of cervical
lymph node and a portion of submandibular gland were performed. These histopathological findings subsequently
confirmed a diagnosis of marginal zone B cell lymphoma.
Conclusion: Differential diagnosis of IgG4-DS is necessary from other disorders, including Sjögren’s syndrome, sarcoidosis,
Castleman’s disease, Wegener’s granulomatosis, lymphoma, and cancer. We suggest that biopsy of swollen lesions is
important for a definitive diagnosis of IgG4-DS and discuss the mechanism of development in this case.
Keywords: IgG4-related dacryoadenitis and sialoadenitis, IgG4-related disease, Marginal zone B cell lymphoma,
Mikulicz’s disease, BiopsyBackground
IgG4-related dacryoadenitis and sialoadenitis (IgG4-DS),
also known as Mikulicz’s disease (MD), is a unique condi-
tion characterized by enlargement of the lacrimal and saliv-
ary glands caused by infiltration of lymphocytes. IgG4-DS
has been considered a subtype of Sjögren’s syndrome (SS)
because of certain histopathological similarities, particularly
lymphocytic infiltration [1]. However, IgG4-DS patients
show elevated serum levels of IgG4 and infiltrating IgG4-
positive plasma cells in the glandular tissues [2,3]. Similar
findings have also been identified in other diseases such as
autoimmune pancreatitis [4], interstitial pneumonia [5],
retroperitoneal fibrosis [6], and sclerosing cholangitis [7],
and these diseases are now referred to as ‘IgG4-related* Correspondence: moriyama@dent.kyushu-u.ac.jp
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unless otherwise stated.disease (IgG4-RD)’ [8]. IgG4-DS is now diagnosed by both
‘Comprehensive diagnostic criteria for IgG4-related disease
(2011)’ and ‘Diagnostic criteria for IgG4-related Mikulicz’s
disease D’ approved by the Japanese Society for Sjögren’s
syndrome [9]. However, it is important to differentiate
IgG4-RD from malignant tumors (such as cancer, lymph-
oma) and similar diseases (such as SS, primary sclerosing
cholangitis, Castleman’s disease, secondary retroperitoneal
fibrosis, Wegener’s granulomatosis, sarcoidosis, Churg-
Strauss syndrome) by histopathological examination of
local lesion. We reported the first case of IgG4-producing
marginal zone B cell lymphoma (MZL) in salivary glands
mimicking IgG4-DS.Case presentation
A 70-year-old man was referred to our institution with bi-
lateral continuous painless swelling of the parotid glands
(PGs) and submandibular glands (SMGs) in March 2013.his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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complaints of dry mouth and bilateral swelling of SMGs,
which were diagnosed as chronic sialoadenitis by computed
tomography (CT) in January 2013. However, he did not re-
ceive any treatment at that time and ignored the swelling.
He had no medical history of allergic diseases such as bron-
chial asthma, atopic dermatitis, or allergic rhinitis.
Physical findings showed no fever (body temperature,
36.6°C), a blood pressure of 124/68 mmHg, a pulse rate of
64 beats per min, and arterial oxygen saturation of 98% in
room air. He had a dry mouth and stomatitis with reduced
unstimulated salivary flow rate (0.9 ml/15 min). Bilateral
PGs, SMGs, and sublingual glands were elastic, hard, and
swollen, but not painful. Several cervical lymph nodes
were enlarged. F-18 fluorodeoxyglucose positron emission
tomography (FDG-PET) demonstrated abnormal multipleFigure 1 Imaging findings before treatment. (A) Fluorodeoxyglucose p
accumulations in the submandibular glands (SMGs) (white arrowheads) and
tomography (CT) findings indicating swelling of the parotid glands (PGs) (w
nodes (LNs) (white arrows). (C) Sonographic images indicating bilateral nodaccumulations in the SMGs (SUVmax, 4.63) and in several
systemic lymph nodes (SUVmax, 3.23–4.12) (Figure 1A).
CT and magnetic resonance imaging showed remarkable
swelling of bilateral PGs, SMGs, and generalized lymph
nodes, including in the neck (Figure 1b). On ultrasono-
grams, SMGs showed bilateral nodal hypoechoic areas
with high vascularization, whereas PGs showed normal or
slight change (Figure 1C).
Laboratory findings are indicated in Table 1. He had an
increased erythrocyte sedimentation rate (15 mm/h),
hemoglobin concentration of 12.6 g/dl, white blood cell
count of 4,680/mm3 (neutrophils 40.7%, lymphocytes 49.8%,
monocytes 8.5%, eosinophils 0.4%, basophils 0.6%), and
platelet count of 12.6 × 104/mm3. Serum chemistry data
were all within normal limits. His C-reactive protein con-
centration was 0.07 mg/dl. Immunological tests wereositron emission tomography (FDG-PET) indicating abnormal multiple
in several systemic lymph nodes (black arrowheads). (B) Computed
hite arrowheads), SMGs (white arrowheads), and generalized lymph
al hypoechoic areas in the SMGs.
Table 1 Laboratory data before and after treatment
Treatment Reference
rangeBefore After
WBC (/mm3) 4,680 3,620 3,500–9,000
Neutrophils (%) 40.7 - 40.0–70.0
Lymphocytes (%) 49.8 37.0 18.0–53.0
Monocytes (%) 8.5 12.5 2.0–12.0
Eosinophils (%) 0.4 2.5 1.0–4.0
Basophils (%) 0.6 3.0 0.0–1.0
Hemoglobin (g/dl) 12.6 13.9 14.0–18.0
Palate (104/mm3) 12.6 16.6 14.0–44.0
ESR (mm/h) 12 - 2–10
Total protein (g/dl) 6.6 6.5 6.7–8.3
Albumin (g/dl) 4.0 4.3 4.0–5.0
LDH (U/L) 182 177 119–229
CRP (mg/dl) 0.07 0.02 <0.10
IgG (mg/dl) 1,177 993 872–1,815
IgG4 (mg/dl) 215 195 4.8–105
IgA (mg/dl) 179 196 95–405
IgM (mg/dl) 91 66 31–190
IgE (mg/dl) 15 - <240
sIL-2R (U/ml) 1,566.2 752.0 206.0–713.0
WBC white blood cell, ESR erythrocyte sedimentation rate, CRP C-reactive
protein, sIL-2R soluble interleukin-2 receptor. Bold and italicized numbers
indicate abnormal values.
Figure 2 Histological findings in submandibular glands. (A) Severe lympho
colonization’ (white arrowheads). (B) mild infiltration of IgG4-positive plasma cells
predominance of kappa-light chain. (D) Infiltrating lymphocytes were positive for
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and rheumatoid factor. Serum levels of IgG, IgA, IgM, and
IgE were within normal limits (1,177 mg/dl, 179 mg/ml,
91 mg/dl, and 15 IU/ml, respectively), but his serum IgG4
concentration was elevated (215 mg/dl). The proportion
of total IgG molecules that were subclass IgG4 was 18%.
The serum soluble interelukin-2 receptor (sIL-2R) concen-
tration was abnormally high (1,566.2 U/ml).
IgG4-DS was initially suspected because of the en-
larged glandular tissues and high serum IgG4 concentra-
tion. Open biopsies of the cervical lymph node and a
portion of the left SMG were therefore performed for
definitive diagnosis. Histologically, all sections showed
severe lymphoplasmacytic infiltration with hyperplastic
lymphoid follicles, so-called follicular colonization. Further-
more, the plasmacytoid cells showed nuclear pleomorphism.
Immunohistochemical staining showed mild infiltration
of IgG4-positive plasma cells (IgG4-positive/IgG-positive
plasma cell ratio, 10%) and monotypic predominance of
kappa-light chain. The infiltrating lymphocytes were positive
for B cell markers (CD20 and CD79a) and bcl-2, but nega-
tive for T-cell markers (CD3, CD5, CD8, and CD45RO),
CD10 and cyclinD1 (Figure 2).
These histopathological findings and clinical features
confirmed a diagnosis of MZL. The patient was treated
with 600 mg rituximab for six times as currently recom-
mended regimen [9-11]. Swelling of the SMGs dimin-
ished slightly, and there was no metastatic spread. PGs
and LNs showed no remarkably change on all images,plasmacytic infiltration with hyperplastic lymphoid follicles, so-called ‘follicular
(IgG4-positive/IgG-positive plasma cell ratio, 10%). (C) Monotypic
B cell markers (CD79a), but negative for T-cell markers (CD3).
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choic areas (Figure 3). Laboratory findings after treat-
ment still revealed high concentrations of serum IgG4
(195 mg/dl) and sIL-2R (752.0 U/ml) (Table 1).
Conclusions
IgG4-DS is now recognized as a new emerging disorder,
characterized by high serum IgG4, marked infiltration of
IgG4-positive plasma cells and severe fibrosis with hyper-
plastic ectopic germinal centers in lacrimal and salivary
glands. We recently proposed ‘Comprehensive diagnostic
criteria for IgG4-RD’ [12]. IgG4-RD can be diagnosed using
these comprehensive diagnostic criteria combined with
organ-specific criteria. If a diagnosis of IgG4-DS is probable
or possible based on these criteria, it can be confirmed
according to the ‘Diagnostic criteria for IgG4-related Miku-
licz’s disease’ approved by the Japanese Society for Sjögren’sFigure 3 Imaging findings after treatment. (A) FDG-PET indicating unchan
and in several systemic lymph nodes (black arrowheads). (B) CT findings indic
and generalized lymph nodes (LNs) (white arrows). (C) Sonographic images insyndrome in 2008, which include the following items: (i)
persistent (longer than 3 months) symmetrical swelling of
more than two lacrimal and major salivary glands, (ii) raised
serum levels of IgG4 (>135 mg/dl), and (iii) infiltration of
IgG4-positive plasma cells in the tissue (IgG4-positive
plasma cells/IgG-positive plasma cells >0.4) by immuno-
staining. For a positive IgG4-DS diagnosis, any two of these
three criteria must be fulfilled, including item (i). The
present case met criteria (i) and (ii), and IgG4-DS was
therefore strongly suspected. However, biopsy of the local
lesion is recommended for differential diagnosis from other
disorders, including sarcoidosis, Castleman’s disease, Wege-
ner’s granulomatosis, lymphoma, and cancer. We therefore
performed the cervical lymph node and SMG biopsies,
resulting in a definitive diagnosis of MZL. These results
suggest that biopsy of the swollen lesion is essential for a de-
finitive diagnosis of IgG4-DS. Moreover, we have commonlyged abnormal multiple accumulations in the SMGs (white arrowheads)
ating swelling of the PGs (white arrowheads), SMGs (white arrowheads),
dicating vaguely-outlined hypoechoic areas in the SMGs.
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local anesthesia, with no complications including facial
palsy, sialoceles, or wound infections. Open biopsy is thus a
relatively low-invasive procedure and useful for the definitive
diagnosis of IgG4-DS [13].
Isabel et al. [14] reported IgG4 expression in MZLs of
various primary sites. According to their paper, 19 out of
49 (38.8%) cutaneous MZLs were positive for IgG4 expres-
sion, while only 1 out of 120 (0.8%) other MZLs were posi-
tive, especially all of 20 salivary gland MZLs showed no
IgG4 expression. Therefore, salivary gland MZL positive
for IgG4 as in this case is very rare. Several studies have
reported IgG4-associated conditions in parts of malignant
lymphoma of the ocular adnexal and lymph nodes [15].
However, IgG4-positive cells were non-neoplastic, and this
IgG4-related chronic inflammation is thought to be a
background for the development of malignant lymph-
oma [16,17]. In contrast, IgG4-producing lymphoma
(non-associated IgG4-RD) also exists [18], in which the
IgG4-producing cells are neoplastic and monoclonal re-
arrangement bands can be observed by Southern blot
hybridization.
Single-agent therapy of rituximab is not effective for
MZL but for IgG4-RD [19]. In this case, the clinical
findings, images, and laboratory examinations showed
no remarkably improvement after treatment for rituxi-
mab for six times. His serum IgG4 concentration levels
remained high and swelling of salivary glands was nearly
unchanged, which indicated that this case might be
IgG4-producing MZL but not on a background of IgG4-
related chronic inflammation. Unfortunately, we were
unable to confirm a strong infiltration of IgG4-positive
cells in the biopsy specimens, and more case reports and
further examinations are required to clarify the clinico-
pathological features of IgG4-RD.
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